HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 443953Erstellt: 23. Oktober 2026
Erythromycinethylsuccinat
Esinol · Evesin · Refkas · Anamycin · Arpimycin · E-Mycin e · Eryliquid · Monomycin
https://huagongshe.com/de/chemical/443953
Identifikatoren & physikalische Daten
| CAS No. | 1264-62-6 |
|---|
| Summenformel | C43H75NO16 |
|---|
| Durchschnittliche Molmasse | 862,1 g/mol |
|---|
| Monoisotopische Masse | 861,50858532 g/mol |
|---|
| SMILES | CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C |
|---|
| InChIKey | NSYZCCDSJNWWJL-YXOIYICCSA-N |
|---|
| PubChem CID | 443953 |
|---|
| ChEMBL | CHEMBL1200688 |
|---|
| ChEBI | CHEBI:31555 |
|---|
| EC No. | 215-033-8 |
|---|
| DTXSID | DTXSID4022993 |
|---|
| Lokaler Name | Erythromycinethylsuccinat |
|---|
Chemische & physikalische Eigenschaften
| XLogP | 3,4 |
|---|
| Polarare Oberfläche (TPSA) | 226 |
|---|
| H-Brücken-Donoren | 4 |
|---|
| H-Brücken-Akzeptoren | 17 |
|---|
| Frei drehbare Bindungen | 14 |
|---|
| Schwere Atome | 60 |
|---|
| Formalladung | 0 |
|---|
| Komplexität | 1.450 |
|---|
| Arzneimittel | Pharmaceuticals -> Antibiotics |
|---|
| Lipide | Polyketides [PK] -> Ansamycins and related polyketides [PK05] |
|---|
| Geruch | ODORLESS OR PRACTICALLY SO |
|---|
| Geschmack | PRACTICALLY TASTELESS |
|---|
| Color/Form | WHITE OR SLIGHTLY YELLOW, CRYSTALLINE POWDER |
|---|
| Löslichkeit | FREELY SOL IN ACETONE & CHLOROFORMSOL IN 95% ETHANOL & BENZENESPARINGLY SOL IN ETHERVERY SLIGHTLY SOL IN WATERFREELY SOLUBLE IN ALC, SOL IN POLYETHYLENE GLYCOLethanol: soluble50mg/mLFreely soluble in organic solvents, practically insoluble in water |
|---|
| Human Drugs | FDA approved drugs -> Active ingredient |
|---|
| Brechungsindex | INDEX OF REFRACTION: 1.490 (ALPHA), 1.515 (BETA), 1.567 (GAMMA)1.5280 (estimate) |
|---|
| Stability/Shelf Life | AFTER RECONSTITUTION OF COMMERCIALLY AVAILABLE POWDER, SUSPENSIONS ARE STABLE FOR 10 DAYS @ 2-8 °CCOMMERCIALLY AVAILABLE TABLETS & POWDER FOR ORAL SUSPENSION HAVE EXPIRATION DATES OF 2 YR FOLLOWING DATES OF MANUFACTURECOMMERCIALLY AVAILABLE SUSPENSIONS HAVE EXPIRATION DATES OF 18 MONTHS FOLLOWING DATES OF MANUFACTUREERYTHROMYCIN ETHYLSUCCINATE IM INJECTION HAS AN EXPIRATION DATE OF 18 MONTHS FOLLOWING DATE OF MFR |
|---|
| Dissociation Constants | PKA 7.1 |
|---|
| Collision Cross Section | 257.7 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
|---|
| Schmelzpunkt | 219-224 C |
|---|
| Siedepunkt | 778.19°C (rough estimate) |
|---|
| Dichte | 1.1417 (rough estimate) |
|---|
| Flammpunkt | >110°(230°F) |
|---|
| Lagerbedingungen | Sealed in dry,Room Temperature |
|---|
| Aggregatzustand | solid |
|---|
| pKa (Säurekonstante) | 13.09±0.70(Predicted) |
|---|
| Farbe | white |
|---|
| Stabilität | Hygroscopic |
|---|
| Hauptanwendungen | pharmaceuticalpharmaceutical small molecule |
|---|
| InChIKey | NSYZCCDSJNWWJL-UHFFFAOYSA-N |
|---|
| SMILES | C1(OC(=O)CCC(OCC)=O)C(N(C)C)CC(C)OC1OC1C(CC(C(C(C(O)C(O)(C)C(CC)OC(=O)C(C)C(OC2OC(C)C(O)C(C)(OC)C2)C1C)C)=O)C)(O)C |
|---|
| CAS Datenbank | 1264-62-6 |
|---|
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH317 (29.9%): May cause an allergic skin reaction [Warning Sensitization, Skin]P233, P260, P261, P264+P265, P271, P272, P280, P284, P302+P352, P304+P340, P305+P351+P338, P321, P333+P317, P337+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 144 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|
| Weitere Sicherheitsinformationen | IMAP assessments - Erythromycin, 2'-(ethyl butanedioate): Environment tier I assessment |
|---|
| Hazard Classes and Categories | Skin Sens. 1 (29.9%) |
|---|
| Human Toxicity Excerpts | AMONG HYPERSENSITIVITY REACTIONS ARE FEVER, EOSINOPHILIA, & SKIN ERUPTIONS, EACH OF WHICH MAY OCCUR ALONE OR IN COMBINATIONTHEY DISAPPEAR SHORTLY AFTER THERAPY IS STOPPED. ...MAY PRODUCE IRRITATIVE EFFECTS. ORAL ADMIN...FREQUENTLY ACCOMPANIED BY EPIGASTRIC DISTRESS, WHICH MAY BE QUITE SEVERE. /ERYTHROMYCIN/IM INJECTION OF QUANTITIES LARGER THAN 100 MG PRODUCES...SEVERE PAIN... PERSISTS FOR HR: IV PERFUSIONS OF 1-G DOSES...ALMOST REGULARLY IS FOLLOWED BY THROMBOPHLEBITIS. ...6 PT...DEVELOPED DIFFICULTY IN HEARING WHILE BEING TREATED WITH 4 G/DAY...IV. ... CESSATION...LED TO COMPLETE RETURN OF NORMAL HEARING... /ERYTHROMYCIN/A CASE REPORT OF HEPATOTOXICITY RESULTING FROM ERYTHROMYCIN ETHYLSUCCINATE THERAPY IN 60-YR-OLD FEMALE IS DESCIRBED. |
|---|
| Wassergefährdungsklasse (WGK) | 2 |
|---|
| Zollcode | 29419000 |
|---|
| RTECS-Nr. | WM9800000 |
|---|
| R-Sätze (R) | 42/43-36/37/38 |
|---|
| Toxizität | LD50 oral in mouse: > 10gm/kg |
|---|
| Gefahrensymbole | Xn,Xi |
|---|
| Sicherheitshinweise (S) | 36-26 |
|---|
| Lagerklasse | 11 - Combustible Solids |
|---|
| Gefahrstoffdaten | 1264-62-6(Hazardous Substances Data) |
|---|
| Gefahrenklasse | Resp. Sens. 1Skin Sens. 1 |
|---|